TRECONY: Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma (clinicaltrials.gov) - Apr 30, 2026 - P2 | N=780 | Recruiting | Sponsor: Chiesi Farmaceutici S.p.A. | N=250 ➔ 780
Enrollment change • Trial initiation date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
|